ReviewCurrent cardiology reports2021
Incremental Value of FDG-PET in the Evaluation of Cardiac Masses.
Review in Current cardiology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Advancing cardiac tumor diagnosis: evaluatingAmerican journal of cardiovascular disease · 2026Review
- Incidental detection of left ventricular metastasis from lung squamous cell carcinoma on FDG PET/CT: A rare case report.Asia Oceania journal of nuclear medicine & biology · 2026Article
- MicroRNA Signatures Predict Brain Amyloidosis and Neurodegeneration in Alzheimer's Disease: Insights from [Brain and behavior · 2025Article
- Echocardiography-Guided Radiofrequency Ablation for Cardiac Tumors.JACC. CardioOncology · 2024Article
- Article
- Cardiac Masses and Pseudomasses: An Overview about Diagnostic Imaging and Clinical Background.Medicina (Kaunas, Lithuania) · 2023Review
- Practical Guide to Interpreting Cardiac Magnetic Resonance in Patients with Cardiac Masses.Journal of cardiovascular development and disease · 2023Review
- Multimodality Imaging of Benign Primary Cardiac Tumor.Diagnostics (Basel, Switzerland) · 2022Review
- Case report: multi-modality imaging of a right ventricular fibroma in a teenager.European heart journal. Case reports · 2022Article
- Current status of diagnosis and treatment of primary benign cardiac tumors in children.Frontiers in cardiovascular medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis study aims to review the various roles and evidence underlying the use of fluorodeoxyglucose (FDG) PET/CT and PET/MR for the assessment of cardiac masses. RECENT
findingsThe role of FDG-PET for the evaluation of cardiac masses continues to evolve. Studies have shown that FDG-PET is particularly well-suited for differentiating malignant from benign cardiac lesions based on their metabolic activity. Furthermore, FDG-PET is uniquely positioned to investigate patients with cardiac mass as most malignant cardiac lesions are metastasis. Finally, FDG-PET enables staging of patients with primary malignant cardiac tumor, identification of potential biopsy site, and planning of radiotherapy. FDG-PET is a complementary tool for the evaluation of patients with cardiac mass and can help differentiate benign from malignant lesions, as well as provide whole-body staging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.